home / stock / kalv / kalv quote
Last: | $11.79 |
---|---|
Change Percent: | 1.45% |
Open: | $11.55 |
Close: | $11.79 |
High: | $12.07 |
Low: | $11.45 |
Volume: | 267,568 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$11.79 | $11.55 | $11.79 | $12.07 | $11.45 | 267,568 | 07-05-2024 |
$11.72 | $11.44 | $11.72 | $11.76 | $11.44 | 139,487 | 07-04-2024 |
$11.72 | $11.44 | $11.72 | $11.76 | $11.44 | 139,487 | 07-03-2024 |
$11.51 | $11.91 | $11.51 | $12 | $11.48 | 249,948 | 07-02-2024 |
$11.89 | $11.66 | $11.89 | $11.98 | $11.53 | 306,543 | 07-01-2024 |
$11.78 | $12.2 | $11.78 | $12.2 | $11.42 | 2,314,196 | 06-28-2024 |
$12.05 | $11.29 | $12.05 | $12.06 | $11.265 | 251,697 | 06-27-2024 |
$11.31 | $11.56 | $11.31 | $11.89 | $10.845 | 635,654 | 06-26-2024 |
$11.55 | $11.72 | $11.55 | $11.82 | $11.44 | 172,262 | 06-25-2024 |
$11.72 | $11.77 | $11.72 | $11.97 | $11.61 | 167,750 | 06-24-2024 |
$11.74 | $11.32 | $11.74 | $11.78 | $11.32 | 936,250 | 06-21-2024 |
$11.21 | $11.33 | $11.21 | $11.35 | $11.07 | 161,857 | 06-20-2024 |
$11.37 | $11.77 | $11.37 | $11.82 | $11.28 | 226,976 | 06-19-2024 |
$11.37 | $11.77 | $11.37 | $11.82 | $11.28 | 226,976 | 06-18-2024 |
$11.82 | $11.99 | $11.82 | $12.1289 | $11.69 | 156,414 | 06-17-2024 |
$12.07 | $12.21 | $12.07 | $12.21 | $11.97 | 229,591 | 06-14-2024 |
$12.26 | $12.35 | $12.26 | $12.56 | $12.06 | 168,336 | 06-13-2024 |
$12.35 | $12.47 | $12.35 | $12.66 | $12.17 | 302,133 | 06-12-2024 |
$12.18 | $11.9 | $12.18 | $12.24 | $11.866 | 188,010 | 06-11-2024 |
$12.04 | $11.61 | $12.04 | $12.14 | $11.59 | 203,078 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...
– US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours – – Despite growing use of long-term prophylaxis therapies in the US on-demand treatment prescription volumes stay stable...